Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.

@article{Hainsworth2005TreatmentOM,
  title={Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.},
  author={John D Hainsworth and Jeffrey A. Sosman and David Robert Spigel and Donna L Edwards and Cara L Baughman and Anthony F Greco},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2005},
  volume={23 31},
  pages={
          7889-96
        }
}
PURPOSE To evaluate the efficacy and toxicity of combined treatment with two targeted agents, an antibody against vascular endothelial growth factor (bevacizumab) and an epidermal growth factor receptor tyrosine kinase inhibitor (erlotinib), in the treatment of patients with metastatic clear-cell renal carcinoma. PATIENTS AND METHODS Sixty-three patients with metastatic clear-cell renal carcinoma were treated with bevacizumab 10 mg/kg intravenously every 2 weeks and erlotinib 150 mg orally… CONTINUE READING
Highly Cited
This paper has 99 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 107 citations

99 Citations

01020'07'10'13'16'19
Citations per Year
Semantic Scholar estimates that this publication has 99 citations based on the available data.

See our FAQ for additional information.